Novel TNFα inhibitor, certolizumab pegol

Peter Y. Shane; Sadayoshi Onodera

doi:10.2745/dds.29.160

Novel TNFα inhibitor, certolizumab pegol

Peter Y. Shane, Sadayoshi Onodera

Research output: Contribution to journal › Article › peer-review

Abstract

Certolizumab pegol (CZP), a novel biological agent, is a PEGylated Fab' fragment of a humanized anti-human TNFα monoclonal antibody. CZP has shown unique pharmacokinetic and pharmacodynamic profiles compared to conventional anti-TNF agents. These characteristics are thought to be the results of its unique structural features, including monovalence, lack of Fc, and PEGylation. CZP rapidly ameliorated signs and symptoms of rheumatoid arthritis (RA), prevented progression of joint destruction, and improved health-related quality of life in patients with active RA. CZP was approved in Japan for the treatment of RA in December 2012.

Original language	English (US)
Pages (from-to)	160-165
Number of pages	6
Journal	Drug Delivery System
Volume	29
Issue number	2
DOIs	https://doi.org/10.2745/dds.29.160
State	Published - 2014
Externally published	Yes

ASJC Scopus subject areas

Pharmaceutical Science

Access to Document

10.2745/dds.29.160

Cite this

@article{d6f8deccdb444c25a8e7f0f0b5174d62,

title = "Novel TNFα inhibitor, certolizumab pegol",

abstract = "Certolizumab pegol (CZP), a novel biological agent, is a PEGylated Fab' fragment of a humanized anti-human TNFα monoclonal antibody. CZP has shown unique pharmacokinetic and pharmacodynamic profiles compared to conventional anti-TNF agents. These characteristics are thought to be the results of its unique structural features, including monovalence, lack of Fc, and PEGylation. CZP rapidly ameliorated signs and symptoms of rheumatoid arthritis (RA), prevented progression of joint destruction, and improved health-related quality of life in patients with active RA. CZP was approved in Japan for the treatment of RA in December 2012.",

author = "Shane, {Peter Y.} and Sadayoshi Onodera",

year = "2014",

doi = "10.2745/dds.29.160",

language = "English (US)",

volume = "29",

pages = "160--165",

journal = "Drug Delivery System",

issn = "0913-5006",

publisher = "Japan Society of Drug Delivery System",

number = "2",

}

TY - JOUR

T1 - Novel TNFα inhibitor, certolizumab pegol

AU - Shane, Peter Y.

AU - Onodera, Sadayoshi

PY - 2014

Y1 - 2014

N2 - Certolizumab pegol (CZP), a novel biological agent, is a PEGylated Fab' fragment of a humanized anti-human TNFα monoclonal antibody. CZP has shown unique pharmacokinetic and pharmacodynamic profiles compared to conventional anti-TNF agents. These characteristics are thought to be the results of its unique structural features, including monovalence, lack of Fc, and PEGylation. CZP rapidly ameliorated signs and symptoms of rheumatoid arthritis (RA), prevented progression of joint destruction, and improved health-related quality of life in patients with active RA. CZP was approved in Japan for the treatment of RA in December 2012.

AB - Certolizumab pegol (CZP), a novel biological agent, is a PEGylated Fab' fragment of a humanized anti-human TNFα monoclonal antibody. CZP has shown unique pharmacokinetic and pharmacodynamic profiles compared to conventional anti-TNF agents. These characteristics are thought to be the results of its unique structural features, including monovalence, lack of Fc, and PEGylation. CZP rapidly ameliorated signs and symptoms of rheumatoid arthritis (RA), prevented progression of joint destruction, and improved health-related quality of life in patients with active RA. CZP was approved in Japan for the treatment of RA in December 2012.

UR - http://www.scopus.com/inward/record.url?scp=84940343177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940343177&partnerID=8YFLogxK

U2 - 10.2745/dds.29.160

DO - 10.2745/dds.29.160

M3 - Article

AN - SCOPUS:84940343177

SN - 0913-5006

VL - 29

SP - 160

EP - 165

JO - Drug Delivery System

JF - Drug Delivery System

IS - 2

ER -

Novel TNFα inhibitor, certolizumab pegol

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this